Randomized trial · people

Amycretin: HbA1c fell up to 1.7% at 36 weeks in type 2 diabetes

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In adults with type 2 diabetes, every amycretin dose tested from 0.4 to 40 mg lowered HbA1c more than placebo over 36 weeks, and the side effects were mostly gut-related.

Kind
Randomized trial
Studied in
People
Number studied
262
Published
2026
Journal
Lancet

What they tested

The team tested how different weekly doses of amycretin (now called zenagamtide), injected under the skin, changed blood sugar control and safety compared with placebo in adults with type 2 diabetes.

How the study was done

A randomized, double-blind, placebo-controlled phase 2 trial that enrolled 262 adults with type 2 diabetes at 83 sites in 11 countries; everyone was on a steady metformin dose, and some also used an SGLT2 inhibitor. For 36 weeks, each person got one of six weekly doses (0.4, 1.5, 5, 10, 20 or 40 mg) or placebo (a dummy shot), starting at 0.2 mg and stepping up every 4 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking amycretin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Average HbA1c (a 3-month average of blood sugar) was 7.8% at the start. By week 36, it fell by 0.9% in the 0.4 mg arm, a difference of -0.77% versus placebo (95% CI -1.26 to -0.28), and by 1.7% in the 40 mg arm, a difference of -1.56% versus placebo (95% CI -2.05 to -1.07). Most side effects involved the gut and were mild to moderate. Serious adverse events occurred in 21 (8%) of 261 treated participants, 3 of them on placebo, and no one died.

What it doesn’t show

This was a 36-week dose-finding trial with a small placebo group of 37 people, all of them adults with type 2 diabetes on background metformin. It was funded by Novo Nordisk.

The paper

Mora et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026.

The compound

More studies on Amycretin

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking amycretin? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo